Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

@article{Andtbacka2015TalimogeneLI,
  title={Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.},
  author={R. Andtbacka and H. Kaufman and F. Collichio and T. Amatruda and N. Senzer and J. Chesney and K. Delman and L. Spitler and I. Puzanov and S. Agarwala and M. Milhem and L. Cranmer and B. Curti and K. Lewis and M. Ross and T. Guthrie and G. Linette and G. Daniels and K. Harrington and M. Middleton and W. Miller and J. Zager and Y. Ye and Bin Yao and A. Li and S. Doleman and A. VanderWalde and J. Gansert and R. Coffin},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 25},
  pages={
          2780-8
        }
}
  • R. Andtbacka, H. Kaufman, +26 authors R. Coffin
  • Published 2015
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Talimogene laherparepvec (T-VEC) is a herpes simplex virus type 1-derived oncolytic immunotherapy designed to selectively replicate within tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic antitumor immune responses. T-VEC was compared with GM-CSF in patients with unresected stage IIIB to IV melanoma in a randomized open-label phase III trial. PATIENTS AND METHODS Patients with injectable melanoma that was not surgically resectable were… Expand
1,290 Citations
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma
The safety of talimogene laherparepvec for the treatment of advanced melanoma
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
An evaluation of talimogene laherparepvec for the treatment of melanoma
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 75 REFERENCES
Improved survival with ipilimumab in patients with metastatic melanoma.
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
  • M. Middleton, Jj Grob, +16 authors N. Thatcher
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2000
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Interleukin-2-based immunotherapy and chemoimmunotherapy in metastatic melanoma.
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
Phase I/II study of ipilimumab for patients with metastatic melanoma.
  • J. Weber, S. O’Day, +5 authors E. Hersh
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
...
1
2
3
4
5
...